Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full …
WEBDec 11, 2020 · The Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to: prevent COVID-19 in individuals 12 years of age and older, and; provide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise
Pfizer and BioNTech Announce Further Details on …
WEBApr 9, 2020 · Pfizer and BioNTech to jointly develop COVID-19 vaccine, initially in the United States and Europe, and scale-up manufacturing capacity to support global supply
The Pfizer BioNTech (BNT162b2) COVID-19 vaccine: What you …
WEBAug 18, 2022 · This article provides a summary of the interim recommendations for the use of the Pfizer BioNTech (BNT162b2) vaccine against COVID-19 issued by WHO Strategic Advisory Group of Experts on Immunization (SAGE).
Pfizer and BioNTech Submit for U.S. Emergency Use …
WEBMar 1, 2023 · NEW YORK and MAINZ, GERMANY, March 1, 2023 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of a booster (fourth) dose of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in …
FDA Authorizes Booster Dose of Pfizer-BioNTech COVID-19 …
WEBSep 22, 2021 · Since Dec. 11, 2020, the Pfizer-BioNTech COVID-19 Vaccine has been available under EUA for individuals 16 years of age and older. The authorization was expanded on May 10, 2021 to include those 12 ...
Pfizer and BioNTech Submit Application to U.S. FDA for …
WEBSep 26, 2022 · Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) of a 10-µg booster dose of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children ages 5 …
Pfizer and BioNTech Provide Update on Booster Program in Light …
WEBJul 8, 2021 · The Pfizer-BioNTech COVID19 Vaccine is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older.
FDA Approves First COVID-19 Vaccine | FDA
WEBAug 23, 2021 · The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now be marketed as Comirnaty (koe-mir’-na-tee), for the prevention of COVID-19 disease in individuals 16...
Overview of COVID-19 Vaccines | CDC
WEBJan 12, 2024 · As of September 12, 2023, the 2023–2024 updated Pfizer-BioNTech and Moderna COVID-19 vaccines were recommended by CDC for use in the United States. Pfizer-BioNTech COVID-19 Vaccine (2023–2024 Formula) is authorized for children ages 6 months–11 years; COMIRNATY is the licensed Pfizer-BioNTech product for people …
Pfizer and BioNTech Announce U.S. FDA Approval of their COVID …
WEBJul 8, 2022 · Pfizer-BioNTech COVID-19 Vaccine is FDA authorized under Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 6 months of age and older.
- Some results have been removedSome results have been hidden because they may be inaccessible to you.Show inaccessible results
Skip to content